MILONTIN Drug Patent Profile
When do Milontin patents expire, and when can generic versions of Milontin launch?
Milontin is a drug marketed by Parke Davis and is included in one NDA.
The generic ingredient in MILONTIN is phensuximide. There is one drug master file entry for this compound. Additional details are available on the phensuximide profile page.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for MILONTIN?
- What are the global sales for MILONTIN?
- What is Average Wholesale Price for MILONTIN?
Summary for MILONTIN
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 61 |
| Patent Applications: | 2,605 |
| DailyMed Link: | MILONTIN at DailyMed |
US Patents and Regulatory Information for MILONTIN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Parke Davis | MILONTIN | phensuximide | CAPSULE;ORAL | 008855-004 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
